Status:
RECRUITING
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Detailed Description
Inclusion criteria: diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT
Eligibility Criteria
Inclusion
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- Potentially Resectable NSCLC
- Treatment Plan is Crizotinb or Standard Chemotherapy
Exclusion
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Key Trial Info
Start Date :
March 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 24 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04324151
Start Date
March 24 2020
End Date
March 24 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongchang Zhang
Changsha, Hunan, China, 410013